Contrarius discloses 0.6% stake in Intellia
Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited report beneficial ownership of 714,480 shares of Intellia Therapeutics, Inc.0.6% of the class as of the event date.
Rhea-AI Filing Summary
Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited report beneficial ownership of 714,480 shares of Intellia Therapeutics, Inc.0.6% of the class as of the event date.
The firms have shared voting and dispositive power over all 714,480 shares and no sole power. They state that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. The filing is made jointly because the two entities may be deemed a group under section 13(d)(3).
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Intellia Therapeutics (NTLA) do Contrarius entities report?
Do Contrarius entities have control intent over Intellia Therapeutics (NTLA)?
Why are two Contrarius entities jointly filing for Intellia (NTLA)?
Is the Contrarius ownership in Intellia (NTLA) above or below 5%?
What type of reporting persons are the Contrarius entities in the Intellia (NTLA) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.